Joel Greshock is Vice President, Data Sciences, Oncology at Janssen Research & Development. In this position, he is responsible for creating unique and actionable medical insights using large and increasingly available datasets.
Prior to joining Janssen R&D, Joel served as Vice President of Bioinformatics at Neon Therapeutics, Inc., where he built and managed the Data Sciences organization. At Neon, he was responsible for the design and deployment of personalized immune therapies for the treatment of cancer. Before joining Neon, Joel served as Head of Oncology Translational Informatics for Novartis, where he led computational efforts focused on the correlation of patient outcomes with molecular biomarkers, identification of mechanisms of clinical resistance and associated research for assets approaching or being evaluated in early phases of clinical development.
Before joining Novartis, Joel assumed numerous roles for GlaxoSmithKline Oncology, which included Head of Bioinformatics and as Compound Development Leader for a PI3K inhibitor in early phase clinical studies. Earlier in his career, Joel was a Data Analyst at Abramson Family Cancer Research Institute at the University of Pennsylvania, where he built early generation microarray platforms and developed widely adopted predictive models for cancer predisposition mutations.
Joel holds a Bachelor of Science in Comprehensive Science and a Master of Science in Biology/Biostatistics, both from Villanova University. He also completed studies at the University of Pennsylvania and Temple University in Statistics and Computer Science.